tiprankstipranks
Abbott Laboratories (DE:ABL)
XETRA:ABL
Holding DE:ABL?
Track your performance easily

Abbott Laboratories (ABL) Stock Forecast & Price Target

10 Followers
See the Price Targets and Ratings of:

ABL Analyst Ratings

Strong Buy
20Ratings
17 Buy
3 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABL Stock 12 Month Forecast

Average Price Target

€128.92
▲(17.56% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is €128.92 with a high forecast of €143.76 and a low forecast of €112.89. The average price target represents a 17.56% change from the last price of €109.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"92":"€92","105":"€105","118":"€118","131":"€131","144":"€144"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143.764885,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€143.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":128.91561265,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€128.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.889205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€112.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[92,105,118,131,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.1,111.76652961538461,114.43305923076923,117.09958884615384,119.76611846153845,122.43264807692307,125.09917769230769,127.76570730769231,130.4322369230769,133.09876653846152,135.76529615384615,138.43182576923076,141.0983553846154,{"y":143.764885,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.1,110.62427789615384,112.14855579230769,113.67283368846154,115.19711158461539,116.72138948076923,118.24566737692308,119.76994527307693,121.29422316923078,122.81850106538462,124.34277896153847,125.86705685769232,127.39133475384617,{"y":128.91561265,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.1,109.3914773076923,109.68295461538462,109.97443192307692,110.26590923076922,110.55738653846154,110.84886384615385,111.14034115384615,111.43181846153846,111.72329576923077,112.01477307692308,112.30625038461538,112.5977276923077,{"y":112.889205,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":97.024,"date":1703203200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.112,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.2,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.027,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.697,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.265,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.988,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.968,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.954,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.318,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.522,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.1,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€143.76Average Price Target€128.92Lowest Price Target€112.89
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
Buy
Reiterated
10/17/24
Citi Keeps Their Buy Rating on Abbott Laboratories (ABT)
Mizuho Securities
€110.96€125.43
Hold
14.38%
Upside
Assigned
10/17/24
Abbott price target raised to $130 from $115 at MizuhoAbbott price target raised to $130 from $115 at Mizuho
UBS
€137.98€140.87
Buy
28.46%
Upside
Reiterated
10/17/24
Abbott price target raised to $146 from $143 at UBSAbbott price target raised to $146 from $143 at UBS
Morgan Stanley
€112.89
Hold
2.94%
Upside
Reiterated
10/17/24
Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
J.P. Morgan
€130.26
Buy
18.78%
Upside
Reiterated
10/16/24
JPMorgan reiterates Overweight Rating on Abbott Labs (ABT)JPMorgan analyst Robbie Marcus reiterated an Overweight rating and $135.00 price target on Abbott Labs (NYSE: ABT)

Best Analysts Covering Abbott Laboratories

Which Analyst Should I Follow If I Want to Buy DE:ABL and Sell After:
1 Month
xxx
Success Rate
16/23 ratings generated profit
70%
Average Return
+1.03%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 69.57% of your transactions generating a profit, with an average return of +1.03% per trade.
3 Months
xxx
Success Rate
19/23 ratings generated profit
83%
Average Return
+5.43%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 82.61% of your transactions generating a profit, with an average return of +5.43% per trade.
1 Year
Rick WiseStifel Nicolaus
Success Rate
24/26 ratings generated profit
92%
Average Return
+19.45%
reiterated a buy rating 2 months ago
Copying Rick Wise's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +19.45% per trade.
2 Years
xxx
Success Rate
26/32 ratings generated profit
81%
Average Return
+16.72%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +16.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABL Analyst Recommendation Trends

Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
0
0
0
0
0
Buy
27
24
36
41
41
Hold
4
6
6
5
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
30
42
46
44
In the current month, ABL has received 41 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ABL average Analyst price target in the past 3 months is €128.92.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ABL Financial Forecast

ABL Earnings Forecast

Next quarter’s earnings estimate for ABL is €1.28 with a range of €1.27 to €1.30. The previous quarter’s EPS was €1.15. ABL beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 53.85% of the time in the same period. In the last calendar year ABL has Outperformed its overall industry.
Next quarter’s earnings estimate for ABL is €1.28 with a range of €1.27 to €1.30. The previous quarter’s EPS was €1.15. ABL beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 53.85% of the time in the same period. In the last calendar year ABL has Outperformed its overall industry.

ABL Sales Forecast

Next quarter’s sales forecast for ABL is €10.50B with a range of €10.35B to €10.68B. The previous quarter’s sales results were €10.13B. ABL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.69% of the time in the same period. In the last calendar year ABL has Outperformed its overall industry.
Next quarter’s sales forecast for ABL is €10.50B with a range of €10.35B to €10.68B. The previous quarter’s sales results were €10.13B. ABL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.69% of the time in the same period. In the last calendar year ABL has Outperformed its overall industry.

ABL Stock Forecast FAQ

What is DE:ABL’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is €128.92.
    What is DE:ABL’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 17.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is €128.92. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €143.76 ,and the lowest forecast is €112.89. The average share price target represents 17.56% Increase from the current price of €109.66.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of DE:ABL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis